Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Arch Biopartners Inc > Why the little guy has the advantage in Arch Bio continued
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by Cb27743on Sep 08, 2021 6:40pm
84 Views
Post# 33828974

RE:RE:Why the little guy has the advantage in Arch Bio continued

RE:RE:Why the little guy has the advantage in Arch Bio continuedVery bullish for Arch. With the Delta variant currently present and the global Covid-19 cases expected to rise in the next coming months. A therapeutic drug that will target the inflammatory response to the lung, kindeys and liver will be a complete game changer to the health care systems across the globe even without Covid-19 related complications. Previous posts mentioned if this drug works, this will be an open door, multi-billion dollar market cap just for the Kidney's alone. Very excited for the upcoming peer/third party Phase II results. What attracts my self to Arch besides the science, is the high insider ownership. Very rare for a Bio-tech company.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities